<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-09-19T16:00:04Z</responseDate><request verb="GetRecord" identifier="oai:dspace.mit.edu:1721.1/17740" metadataPrefix="dim">https://dspace.mit.edu/server/oai/request</request><GetRecord><record><header><identifier>oai:dspace.mit.edu:1721.1/17740</identifier><datestamp>2022-01-13T07:54:21Z</datestamp><setSpec>com_1721.1_7582</setSpec><setSpec>com_1721.1_7581</setSpec><setSpec>col_1721.1_131022</setSpec></header><metadata><dim:dim xmlns:dim="http://www.dspace.org/xmlns/dspace/dim" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://www.dspace.org/xmlns/dspace/dim http://www.dspace.org/schema/dim.xsd">
   <dim:field mdschema="dc" element="contributor" qualifier="advisor" lang="en_US">Bruce Tidor.</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="author" lang="en_US">Sherman, B. Woody (Brian Woody), 1977-</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="other" lang="en_US">Massachusetts Institute of Technology. Dept. of Chemistry.</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="department">Massachusetts Institute of Technology. Department of Chemistry</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="accessioned">2005-06-02T18:27:51Z</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="available">2005-06-02T18:27:51Z</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="copyright" lang="en_US">2004</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="issued" lang="en_US">2004</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="uri">http://hdl.handle.net/1721.1/17740</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="oclc" lang="en_US">56481200</dim:field>
   <dim:field mdschema="dc" element="description" lang="en_US">Thesis (Ph. D.)--Massachusetts Institute of Technology, Dept. of Chemistry, 2004.</dim:field>
   <dim:field mdschema="dc" element="description" lang="en_US">Vita.</dim:field>
   <dim:field mdschema="dc" element="description" lang="en_US">Includes bibliographical references (p. 257-281).</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="abstract" lang="en_US">Theory and methods to design ligands with enhanced binding affinity and specificity for use as biological therapeutics were developed. These methods involve electrostatic charge optimization techniques and packing considerations. First, a detailed investigation of a transition state analog (TSA) binding to the E. coli chorismate mutase enzyme was performed. This study included an electrostatic component analysis of both the ligand and receptor to understands the determinants of binding as well as an optimization of the TSA charges that revealed that the system was well optimized for binding. In another study, a method was developed to predict potential affinity-enhancing modifications to a protein therapeutic. An antibody raised against the VLA-1 [alpha]-1 [beta]-1 integrin was used in this study and several mutation predictions arose that were computed to enhance binding affinity to the target. The set of predictions could be classified into four groups based on their physical characteristics within the system. The residues making long range electrostatic interactions were found to have the highest percentage of computed affinity-enhanced binders. Finally, an extension to the affinity charge optimization theory was implemented that accounted for broad and narrow specificity of binding. An application to the protease of HIV was performed to explore the determinants of specificity. General principles were found in a narrow specificity study with HIV protease as a target and the human aspartyl proteases pepsin and cathepsin D as decoys that may help to elucidate principles for designing more selective inhibitors.</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="abstract" lang="en_US">(cont. ) In a broad specificity study with wild type HIV protease and several escape mutant proteases, we found common features on the protease that could be targeted to create a new generation of HIV protease inhibitors that are not as susceptible to viral resistance as the current therapeutics.</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="statementofresponsibility" lang="en_US">by B. Woody Sherman.</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="degree" lang="en_US">Ph.D.</dim:field>
   <dim:field mdschema="dc" element="format" qualifier="extent" lang="en_US">284 p.</dim:field>
   <dim:field mdschema="dc" element="format" qualifier="extent">11812808 bytes</dim:field>
   <dim:field mdschema="dc" element="format" qualifier="extent">11812609 bytes</dim:field>
   <dim:field mdschema="dc" element="format" qualifier="mimetype">application/pdf</dim:field>
   <dim:field mdschema="dc" element="format" qualifier="mimetype">application/pdf</dim:field>
   <dim:field mdschema="dc" element="language" qualifier="iso" lang="en_US">eng</dim:field>
   <dim:field mdschema="dc" element="publisher" lang="en_US">Massachusetts Institute of Technology</dim:field>
   <dim:field mdschema="dc" element="rights" lang="en_US">M.I.T. theses are protected by copyright. They may be viewed from this source for any purpose, but reproduction or distribution in any format is prohibited without written permission. See provided URL for inquiries about permission.</dim:field>
   <dim:field mdschema="dc" element="rights" qualifier="uri">http://dspace.mit.edu/handle/1721.1/7582</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">Chemistry.</dim:field>
   <dim:field mdschema="dc" element="title" lang="en_US">Biomolecular ligand design : enhancing binding affinity and specificity utilizing electrostatic charge optimization and packing techniques</dim:field>
   <dim:field mdschema="dc" element="type" lang="en_US">Thesis</dim:field>
   <dim:field mdschema="dc" element="format" qualifier="mimetype">application/pdf</dim:field>
   <dim:field mdschema="dspace" element="authorsordered">false</dim:field>
   <dim:field mdschema="dspace" element="entity" qualifier="type">Publication</dim:field>
   <dim:field mdschema="others" element="access-status">unknown</dim:field>
   <dim:field mdschema="others" element="access-status">unknown</dim:field>
   <dim:field mdschema="cerif" element="openaire" authority="" confidence="-1">&lt;Publication xmlns="https://www.openaire.eu/cerif-profile/1.1/" id="d81404e5-fbab-4277-bd03-f4ac6b31a9b2">
	&lt;Type xmlns="https://www.openaire.eu/cerif-profile/vocab/COAR_Publication_Types">http://purl.org/coar/resource_type/c_1843&lt;/Type>
	&lt;Language>eng&lt;/Language>
   	&lt;Title>Biomolecular ligand design : enhancing binding affinity and specificity utilizing electrostatic charge optimization and packing techniques&lt;/Title>
   	&lt;PublishedIn>
    	&lt;Publication>
      	&lt;/Publication>
   	&lt;/PublishedIn>
   	&lt;PublicationDate>2004&lt;/PublicationDate>
   	&lt;Authors>
      	&lt;Author>
        	&lt;DisplayName>Sherman, B. Woody (Brian Woody), 1977-&lt;/DisplayName>
         	&lt;Affiliation>
         		&lt;OrgUnit>
         		&lt;/OrgUnit>
         	&lt;/Affiliation>
      	&lt;/Author>
	&lt;/Authors>
   	&lt;Editors>
	&lt;/Editors>
    &lt;Publishers>
        &lt;Publisher>
            &lt;DisplayName>Massachusetts Institute of Technology&lt;/DisplayName>
            &lt;OrgUnit />
        &lt;/Publisher>
    &lt;/Publishers>
    &lt;License>http://dspace.mit.edu/handle/1721.1/7582&lt;/License>
    &lt;Keyword>Chemistry.&lt;/Keyword>
   	&lt;Abstract>Theory and methods to design ligands with enhanced binding affinity and specificity for use as biological therapeutics were developed. These methods involve electrostatic charge optimization techniques and packing considerations. First, a detailed investigation of a transition state analog (TSA) binding to the E. coli chorismate mutase enzyme was performed. This study included an electrostatic component analysis of both the ligand and receptor to understands the determinants of binding as well as an optimization of the TSA charges that revealed that the system was well optimized for binding. In another study, a method was developed to predict potential affinity-enhancing modifications to a protein therapeutic. An antibody raised against the VLA-1 [alpha]-1 [beta]-1 integrin was used in this study and several mutation predictions arose that were computed to enhance binding affinity to the target. The set of predictions could be classified into four groups based on their physical characteristics within the system. The residues making long range electrostatic interactions were found to have the highest percentage of computed affinity-enhanced binders. Finally, an extension to the affinity charge optimization theory was implemented that accounted for broad and narrow specificity of binding. An application to the protease of HIV was performed to explore the determinants of specificity. General principles were found in a narrow specificity study with HIV protease as a target and the human aspartyl proteases pepsin and cathepsin D as decoys that may help to elucidate principles for designing more selective inhibitors.&lt;/Abstract>
   	&lt;Abstract>(cont. ) In a broad specificity study with wild type HIV protease and several escape mutant proteases, we found common features on the protease that could be targeted to create a new generation of HIV protease inhibitors that are not as susceptible to viral resistance as the current therapeutics.&lt;/Abstract>
	&lt;Access xmlns="http://purl.org/coar/access_right" 
    >
    &lt;/Access>
&lt;/Publication>
</dim:field>
</dim:dim>
</metadata></record></GetRecord></OAI-PMH>